Prognostic score including gene mutations in chronic Myelomonocytic Leukemia

Journal of Clinical Oncology

Volumn 31, Issue 19, 2013, Pages 2428-2436

  Leukemia, Myelomonocytic ^j   Itzykson, Raphaël ^a,b   Kosmider, Olivier ^c,d,e   Renneville, Aline ^a,f   Gelsi Boyer, Véronique ^g   Meggendorfer, Manja ^j   Morabito, Margot ^a,b   Berthon, Céline ^f   Adès, Lionel ^h   Fenaux, Pierre ^h   Beyne Rauzy, Odile ⁱ   Vey, Norbert ^g   Braun, Thorsten ^h   Haferlach, Torsten ^j   Dreyfus, Rançois ^c,d   Cross, Nicholas C P ^k,l   Preudhomme, Claude ^a,f   Bernard, Olivier A ^a   Fontenay, Michaela ^c,d,e   Vainchenker, William ^a,b   Schnittger, Susanne ^j   Birnbaum, Daniel ^g   Droin, Nathalie ^a,b   Solary, Eric ^a,b   more..

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Hôpital Cochin ^*  (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSTITUT COCHIN   (France)

^f UNIV LILLE   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h AVICENNE HOSPITAL   (France)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

^j MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^k UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^l WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ASXL1 PROTEIN; CBL PROTEIN; CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; HEMOGLOBIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; K RAS PROTEIN; N RAS PROTEIN; NUCLEOPHOSMIN; PROTEIN P53; RAS PROTEIN; SF3B1 PROTEIN; SRSF2 PROTEIN; TET2 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1; U2AF1 PROTEIN; UNCLASSIFIED DRUG; ZRSF2 PROTEIN;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ANEMIA; ARTICLE; BOOTSTRAPPING; CANCER PATIENT; CANCER PROGNOSIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE FREE SURVIVAL; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PARAMETERS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SCORING SYSTEM; THROMBOCYTE COUNT; UNIVARIATE ANALYSIS;

EID: 84922336738     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.3314     Document Type: Article

References (65)

1. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114:937-951, 2009
2. Bacher U, Haferlach T, Schnittger S, et al: Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. Br J Haematol 153:149-167, 2011
3. Germing U, Kundgen A, Gattermann N: Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 45:1311-1318, 2004
4. Wattel E, Guerci A, Hecquet B, et al: A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia: Groupe Francais des Myelodysplasies and European CMML Group. Blood 88:2480-2487, 1996
5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 10:223-232, 2009
6. Braun T, Itzykson R, Renneville A, et al: Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: A phase 2 trial. Blood 118:3824-3831, 2011
7. Aribi A, Borthakur G, Ravandi F, et al: Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 109:713-717, 2007
8. Wijermans PW, Ruter B, Baer MR, et al: Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 32:587-591, 2008
9. Costa R, Abdulhaq H, Haq B, et al: Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 117:2690-2696, 2011
10. Ades L, Sekeres MA, Wolfromm A, et al: Prognostic factors of response and survival in CMML patients treated with azacitidine (AZA). ASH Annual Meeting Abstracts 118:1726, 2011 (abstr 1726)
11. Cheng H, Kirtani VG, Gergis U: Current status of allogeneic HST for chronic myelomonocytic leukemia. Bone Marrow Transplant 47:535-541, 2012
12. Fenaux P, Beuscart R, Lai JL, et al: Prognostic factors in adult chronic myelomonocytic leukemia: An analysis of 107 cases. J Clin Oncol 6:1417-1424, 1988
13. Worsley A, Oscier DG, Stevens J, et al: Prognostic features of chronic myelomonocytic leukaemia: A modified Bournemouth score gives the best prediction of survival. Br J Haematol 68:17-21, 1988
14. Gonzalez-Medina I, Bueno J, Torrequebrada A, et al: Two groups of chronic myelomonocytic leukaemia: Myelodysplastic and myeloproliferative-Prognostic implications in a series of a single center. Leuk Res 26:821-824, 2002
15. Onida F, Kantarjian HM, Smith TL, et al: Prognostic factors and scoring systems in chronic myelomonocytic leukemia: A retrospective analysis of 213 patients. Blood 99:840-849, 2002
16. Kantarjian H, O'Brien S, Ravandi F, et al: Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113:1351-1361, 2008
17. Such E, Cervera J, Costa D, et al: Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 96:375-383, 2011
18. Dunbar AJ, Gondek LP, O'Keefe CL, et al: 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 68:10349-10357, 2008
19. Lee BH, Tothova Z, Levine RL, et al: FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell 12:367-380, 2007
20. Levine RL, Loriaux M, Huntly BJ, et al: The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106:3377-3379, 2005
21. Tyner JW, Erickson H, Deininger MW, et al: High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood 113:1749-1755, 2009
22. Makishima H, Cazzolli H, Szpurka H, et al: Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 27:6109-6116, 2009
23. Schnittger S, Bacher U, Alpermann T, et al: Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myeloproliferative/myelodysplastic disorders: An analysis of 636 cases. Haematologica 97:1890-1894, 2012
24. Gelsi-Boyer V, Trouplin V, Adelaide J, et al: Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145:788-800, 2009
25. Abdel-Wahab O, Mullally A, Hedvat C, et al: Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies Blood 114:144-147, 2009
26. Abdel-Wahab O, Pardanani A, Patel J, et al: Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 25:1200-1202, 2011
27. Abdel-Wahab O, Pardanani A, Rampal R, et al: DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 25:1219-1220, 2011
28. Kohlmann A, Grossmann V, Klein HU, et al: Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8 of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 28:3858-3865, 2010
29. Grossmann V, Kohlmann A, Eder C, et al: Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in > 80 of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 25:877-879, 2011
30. Kosmider O, Gelsi-Boyer V, Ciudad M, et al: TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 94:1676-1681, 2009
31. Kosmider O, Gelsi-Boyer V, Slama L, et al: Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 24:1094-1096, 2010
32. Jankowska AM, Szpurka H, Tiu RV, et al: Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 113:6403-6410, 2009
33. Jankowska AM, Makishima H, Tiu RV, et al: Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 118:3932-3941, 2011
34. Smith AE, Mohamedali AM, Kulasekararaj A, et al: Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals lowabundance mutant clones with early origins, but indicates no definite prognostic value. Blood 116:3923-3932, 2010
35. Ernst T, Chase AJ, Score J, et al: Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42:722-726, 2010
36. Yoshida K, Sanada M, Shiraishi Y, et al: Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64-69, 2011
37. Meggendorfer M, Roller A, Haferlach T, et al: SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 120:3080-3088, 2012
38. Kar SA, Jankowska A, Makishima H, et al: Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica 98:107-113, 2012
39. Makishima H, Visconte V, Sakaguchi H, et al: Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 119:3203-3210, 2012
40. Gelsi-Boyer V, Trouplin V, Adelaide J, et al: Genome profiling of chronic myelomonocytic leukemia: Frequent alterations of RAS and RUNX1 genes. BMC Cancer 8:299, 2008
41. Kuo MC, Liang DC, Huang CF, et al: RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia 23:1426-1431, 2009
42. Caudill JS, Sternberg AJ, Li CY, et al: C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders. Br J Haematol 133:638-641, 2006
43. Padua RA, Guinn BA, Al-Sabah AI, et al: RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: A 10-year follow-up. Leukemia 12:887-892, 1998
44. Gelsi-Boyer V, Trouplin V, Roquain J, et al: ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 151:365-375, 2010
45. Greenberg P, Cox C, Le Beau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997
46. Schanz J, Steidl C, Fonatsch C, et al: Coalesced multicentric analysis of 2, 351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 29:1963-1970, 2011
47. Renneville A, Boissel N, Nibourel O, et al: Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: A study by the Acute Leukemia French Association. Leukemia 26:1247-1254, 2012
48. Damm F, Kosmider O, Gelsi-Boyer V, et al: Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 119:3211-3218, 2012
49. Grambsch P, Louis TA, Bostick RM, et al: Statistical analysis of proliferative index data in clinical trials. Stat Med 13:1619-1634, 1994
50. Chen CH, George SL: The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. Stat Med 4:39-46, 1985
51. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996
52. Bejar R, Stevenson K, Abdel-Wahab O, et al: Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496-2506, 2011
53. Bejar R, Stevenson KE, Caughey BA, et al: Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 30:3376-3382, 2012
54. Figueroa ME, Abdel-Wahab O, Lu C, et al: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-567, 2010
55. Quivoron C, Couronne L, Della Valle V, et al: TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20:25-38, 2011
56. Moran-Crusio K, Reavie L, Shih A, et al: Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20:11-24, 2011
57. Ko M, Bandukwala HS, An J, et al: Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A 108:14566-14571, 2011
58. Li Z, Cai X, Cai CL, et al: Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118:4509-4518, 2011
59. Itzykson R, Kosmider O, Renneville A, et al: Clonal architecture of chronic myelomonocytic leukemias. Blood 121:2186-2198, 2013
60. Abdel-Wahab O, Adli M, La Fave LM, et al: ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22:180-193, 2012
61. Vainchenker W, Delhommeau F, Constantinescu SN, et al: New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118:1723-1735, 2011
62. Gelsi-Boyer V, Brecqueville M, Devillier R, et al: Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 5:12, 2012
63. Grossmann V, Schnittger S, Kohlmann A, et al: A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 120:2963-2972, 2012
64. Patel JP, Gonen M, Figueroa ME, et al: Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366:1079-1089, 2012
65. Traina F, Jankowska AM, Visconte V, et al: Impact of molecular mutations on treatment response to hypomethylating agents in MDS blood. Presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego, CA, December 10-13, 2011 (abstr 461)